Switch to:
More From Other Websites
The Risk-to-Reward Ratio of the Pharmacyclics–AbbVie Merger Mar 28 2015
The Pharmacyclics–AbbVie Merger: What Are the Details? Mar 28 2015
European Medicines Agency Validates Marketing Authorisation Application for ZINBRYTA™ (Daclizumab... Mar 27 2015
Read This Before You Sell Gilead Sciences Mar 25 2015
Biotech Stock Roundup: Biogen Soars on Alzheimer's Data, Gilead HCV Drugs Label Update - Analyst... Mar 25 2015
The Pharmacyclics–AbbVie Merger: The Basics of Pharmacyclics Mar 25 2015
Could the Pharmacyclics–AbbVie Merger Get Competitive? Mar 24 2015
Is Antitrust a Risk in the Pharmacyclics–AbbVie Merger? Mar 23 2015
Rationale for the Pharmacyclics–AbbVie Merger Mar 23 2015
Cramer's stocks to watch: Amazing biotech Mar 23 2015
ABBVIE INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and... Mar 23 2015
AbbVie And C2N Enter Into A Worldwide License Agreement For Alzheimer's Disease Therapy Mar 20 2015
ABBVIE INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct... Mar 20 2015
Biotech bulls take charge Mar 20 2015
The Pharmacyclics–AbbVie Merger – Shareholders Could Benefit Mar 20 2015
Viking Global Exited Its Position in AbbVie Mar 20 2015
Celgene's Data on Crohn's Disease Candidate Published - Analyst Blog Mar 19 2015
Aldeyra Initiates Phase II Sjogren-Larsson Syndrome Study - Analyst Blog Mar 19 2015
AbbVie And C2N Enter Into A Worldwide License Agreement For Alzheimer's Disease Therapy Mar 19 2015
AbbVie seeks $30 million expansion of plant in Puerto Rico Mar 18 2015


Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK